The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Share News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.20
Bid: 0.17
Ask: 0.21
Change: 0.01 (5.56%)
Spread: 0.04 (23.529%)
Open: 0.20
High: 0.20
Low: 0.20
Prev. Close: 0.18
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Marlowe executes strategy with whirl of acquisitions

Tue, 02nd Mar 2021 17:12

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Marlowe PLC - London-based safety & compliance services - Acquires HR software business YouManage for GBP1.3 million. Acquires law compliance specialists ESP, ESP Law, and ESP Safeguard for GBP3.2 million. Acquires HR compliance specialist HR Services Partnership for GBP700,000. "These acquisitions are consistent with the three-year strategy recently announced at Marlowe's capital markets day to deepen and broaden our presence in core markets from selective acquisitions," says Marlowe Chief Executive Alex Dacre.

----------

Pantheon Resources PLC - oil & gas exploration company focused on Alaska - Announces the drilling of a new sidetrack into Kuparuk formation at Talitha A well in Alaska after encountering a problem with swelling. "As far as problems go, it's a good problem to have because it was driven by the preliminary data being better than expected at this location and warrants the opportunity to be tested rigorously," says Chief Executive Jay Cheatham.

----------

Nuformix PLC - pharmaceutical development firm based in London - Reports positive results for NXP002, an inhaled tranilast used to treat idiopathic pulmonary fibrosis. Says the study, performed by Newcastle Fibrosis Research Group, examined both the anti-fibrotic and anti-inflammatory potential of NXP002 in combination with the current standard of care, or SOC, therapies. Says the preliminary data from this study shows that the combination of NXP002 with SOC provided strong evidence of additional effects compared to either SOC alone on both fibrotic and inflammatory markers.

----------

Altus Strategies PLC - Africa-focused mining royalty company - Finds broad and high-grade intersections at Tabakorole gold project in Mali. "These are very encouraging drilling results from the Tabakorole gold project in southern Mali. Tabakorole hosts a significant gold resource, which is open along strike in both directions as well as at depth," says Chief Executive Steven Poulton. Says the holes are expected to improve the modelled mineralised grades and widths in a portion of the orebody.

----------

Mycelx Technologies Corp - clean water firm based in Minnesota - Says it has made a strong start to the year with two project extensions signed with customers in Saudi Arabia. "These projects confirm that Mycelx's superior solutions continue to support its customers' efforts to optimise production, increase cost savings and improve energy efficiency," says Mycelx. Expects to commence delivery of the equipment for its third sale to Nigeria in the first quarter of 2020.

----------

Alba Mineral Resources PLC - mineral exploration and development company with assets in Greenland and the UK - Says the physical attributes of the veins intersected at Clogau in Wales reflect the characteristics of the veins that were successfully mined in the past. Says this means that it "could well be a significant contributor to future production", adding that it is necessary to await the results of the drill core assays before reaching any preliminary conclusions.

----------

MGC Pharmaceuticals Ltd - Europe-based biopharmaceutical company - Says Swiss PharmaCan AG increases initial purchase order volume by 85% for first Artemic Rescue production batch, bringing the initial purchase order value to in excess of USD425,000 wholesale revenue to MGC. The initial agreement included a minimum wholesale order quantity of 40,000 units of per quarter. ArtemiC is a clinically tested food supplement containing four natural based ingredients consisting of artemisinin, curcumin, boswellia serrata, and vitamin C.

----------

PetroNeft Resources PLC - Russia-focused oil & gas exploration and production company - Says the hydraulic fracture stimulation program of wells on both the Sibkrayevskoye and the Lineynoye fields successfully completed. Initial results from the wells are "very encouraging". Says the aim of fracking the well was not only to increase production, but also to provide crucial information which can lead to an improved understanding of the optimum forward development plan for the field.

----------

Safestay PLC - hostels operator based in London - Announces sale of 96-bed hostel Barcelona Sea to Beds & Foods Barcelona for EUR900,000. The annual earnings before interest, tax, depreciation and amortisation of the hostel pre Covid-19 was EUR70,000. Says the proceeds will got to paying off the debt for the purchase of another hostel in Barcelona in 2018.

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
28 Jul 2022 16:14

EXECUTIVE CHANGES: Cohort co-founder out; Nuformix co-founder back

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and not separately reported by Alliance News:

Read more
28 Jul 2022 15:01

EARNINGS UPDATES: Alliance Trust beats benchmark and ups dividend

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
29 Jun 2022 12:25

IN BRIEF: Nuformix shares rise as progresses with cancer programme

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Starts to scale-up the production processes of lead cocrystals for its cancer programme NXP004, focused on the treatment for advanced ovarian cancer. Firm aims to develop new forms of Olaparib, "currently marketed by AstraZeneca PLC, under the Lynparza brand name," Nuformix explains. First approved in 2014 for advanced ovarian cancer, it has since received "similar approvals in breast, pancreatic and prostate cancers with further trials on-going."

Read more
27 Jun 2022 21:51

TRADING UPDATES: Anglo-Eastern Plantations sees palm oil prices rise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
31 May 2022 12:41

Nuformix Executive Chair Alastair Riddell resigns after one year

(Alliance News) - Nuformix PLC on Tuesday said Executive Chair Alastair Riddell has resigned with immediate effect.

Read more
30 May 2022 11:54

IN BRIEF: Nuformix shares plunge on inconsistent repeat study results

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says the contract research organisation undertaking the final planned pre-clinical study for its NXP002 treatment had a protocol failure, which has voided the study. Says the organisation repeated the study and recorded results that were inconsistent with the first in vivo study at all time points and also with the oral control. Notes that no positive or negative conclusions could be drawn from this study.

Read more
30 May 2022 11:13

SMALL-CAP WINNERS & LOSERS: Foxtons finds new CEO; S4 revenue surges

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Monday.

Read more
28 Mar 2022 19:18

IN BRIEF: Nuformix NXP004 patent application reaches publication phase

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says patent application for key asset NXP004 had progressed to the publication phase. NXP004 is a new formulation of Olaparib, which is used to treat ovarian, breast and pancreatic cancers currently marketed by FTSE 100-listed AstraZeneca PLC, under the name Lynparza. The patent application, which was made in September 2020, covers new olaparib oxalic acid cocrystals, their therapeutic uses and pharmaceutical compositions containing them. A second patent application was filed last November which remains pending.

Read more
8 Feb 2022 13:58

TRADING UPDATES: Round Hill Music buys Alice In Chains catalogue

TRADING UPDATES: Round Hill Music buys Alice In Chains catalogue

Read more
8 Feb 2022 10:52

SMALL-CAP WINNERS & LOSERS: Nuformix jumps as partner inks contract

SMALL-CAP WINNERS & LOSERS: Nuformix jumps as partner inks contract

Read more
14 Dec 2021 18:01

TRADING UPDATES: Cohort interim loss widens, Yourgene loss narrows

TRADING UPDATES: Cohort interim loss widens, Yourgene loss narrows

Read more
25 Nov 2021 16:23

IN BRIEF: Nuformix notes positive results for inhaled NXP002 dose

IN BRIEF: Nuformix notes positive results for inhaled NXP002 dose

Read more
12 Nov 2021 12:11

TRADING UPDATES: Princess exits Taco Bell; Nuformix files patent

TRADING UPDATES: Princess exits Taco Bell; Nuformix files patent

Read more
12 Nov 2021 10:54

SMALL-CAP WINNERS & LOSERS: Avon Protection plates face approval delay

SMALL-CAP WINNERS & LOSERS: Avon Protection plates face approval delay

Read more
9 Nov 2021 15:30

CORRECT: Nuformix Chair Alastair Riddell to move to executive chair

CORRECT: Nuformix Chair Alastair Riddell to move to executive chair

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.